Bank of America Comments on BCRX Phase-3 Data

Symbols: BCRX
Share

Bank of America has published a report on BioCryst Pharmaceuticals (NASDAQ: BCRX) commenting on the status of phase-3 gout drug (BCX4208).


 
 
< Previous
Green Mountain Coffee up 2% on Unconfirmed Takeover Chatter
Next >
UPDATE: Bank of America Meets with BioCryst Pharma Management on BCX4208
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust